Industrials
Live Price
Offline$0.035
+0.00% today
Window Change
-84.98%
Window
Aug 4, 2025 → May 18, 2026
Historical coverage is still expanding
This 1Y daily history view is usable, but not fully loaded yet. Additional bars will appear as backfills continue.
Coverage: 197 bars · Aug 4, 2025 → May 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Strata Critical Medical, Inc. (SRTAW) is a Industrials stock with a market cap of $440.00M and listed on NASDAQ. The stock last traded around $0.04 and down 85.0% across the available one-year price window (Aug 4, 2025 → May 18, 2026). Baseline metrics include revenue growth of -20.7%, EPS growth of +242.9%, a dividend yield of 0.0%. What stands out right now is revenue -20.7%, EPS +242.9%, free cash flow -64.8% with operating margin -11.3% and ROIC 15.8%. Valuation is more restrained than many high-expectation growth names at P/E 10.1 and price/sales 2.2. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines SRTAW price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Industrials peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SRTAW
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
SRTAW Max Drawdown
-98.14%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for SRTAW and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$50.5M
-65.4% YoY
FY Net Income
-$40.1M
-46.9% YoY
Free Cash Flow
-$16.4M
+56.6% YoY
Revenue Growth
-20.7%
EPS Growth
+242.9%
Gross Margin
20.9%
Net Margin
21.0%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 197M | 249M | 225M | 146M | 51M |
| Gross Profit | 41M | 59M | 42M | 22M | 11M |
| Operating Income | -22M | -34M | -68M | -54M | -24M |
| EBITDA | -12M | -28M | -61M | -70M | -23M |
| Net Income | 41M | -27M | -56M | -27M | -40M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 31M | 18M | 28M | 41M | 3M |
| Total Assets | 325M | 257M | 295M | 325M | 336M |
| Total Liabilities | 46M | 35M | 61M | 51M | 45M |
| Shareholder Equity | 279M | 222M | 234M | 274M | 291M |
| Total Debt | 3M | 9M | 25M | 18M | 716K |
| Net Debt | -28M | -9M | -3M | -23M | -2M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
16M
+57.9% YoY
Capital Expenditures
801K
-9.7% YoY
Free Cash Flow
16M
+56.6% YoY
Key ratios
Gross Margin
20.9%
Operating Margin
-11.3%
Net Margin
21.0%
ROE
16.5%
Debt / Equity
0.01x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.